Welcome to our dedicated page for Promis Neuroscie news (Ticker: PMN), a resource for investors and traders seeking the latest updates and insights on Promis Neuroscie stock.
ProMIS Neurosciences Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company developing therapeutic antibodies and vaccines that selectively target toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases. News about ProMIS frequently centers on its lead Alzheimer’s disease program, PMN310, and the company’s biomarker-driven clinical strategy.
Investors following PMN can expect regular updates on the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer’s disease. Company releases describe PRECISE-AD as a randomized, double-blind, placebo-controlled, multiple ascending dose study evaluating safety, tolerability, pharmacokinetics and biomarker effects of PMN310 in patients with mild cognitive impairment due to AD and mild AD. News items have highlighted enrollment milestones, DSMB recommendations to proceed to higher dose cohorts, and reports that no amyloid-related imaging abnormalities (ARIA) or treatment-related serious adverse events were observed in the cohorts discussed.
ProMIS also issues news on peer-reviewed publications and scientific analyses related to its approach. Recent communications describe publications on the relationship between antibody selectivity for soluble amyloid-beta oligomers and clinical efficacy, as well as analyses supporting plasma phosphorylated tau (pTau) as a potential early predictor of clinical benefit. These publications are referenced by the company as supporting its focus on oligomer-only targeting and its use of plasma pTau as a central endpoint in PRECISE-AD.
Additional PMN news covers corporate and regulatory developments, including the granting of FDA Fast Track designation for PMN310, participation in healthcare investment conferences, board appointments, and capital markets actions such as a one-for-twenty-five reverse stock split and at-the-market offering arrangements. Together, these updates provide context on ProMIS Neurosciences’ clinical progress, scientific rationale and financing activities for those tracking PMN stock and its Alzheimer’s and broader neurodegeneration pipeline.
ProMIS Neurosciences (Nasdaq: PMN) reported its Q1 2024 financial results and corporate updates. The company is progressing with its Phase 1a clinical trial of PMN310 for Alzheimer's disease (AD), expecting top-line data by mid-2024. The trial evaluates safety, tolerability, and pharmacokinetics in healthy volunteers. ProMIS also plans a Phase 1b study in H2 2024. Recent publications support PMN310’s potential. In the ALS program, PMN267 showed promising preclinical data. ProMIS selected PMN400 as a lead vaccine candidate for synucleinopathies. Financially, ProMIS reported a cash decrease to $2.5M, R&D expenses of $2.1M, G&A expenses of $1.6M, and a net loss of $3.6M.
ProMIS Neurosciences Inc. published a study highlighting the selectivity of PMN310 in targeting toxic soluble aggregates in neurodegenerative diseases such as Alzheimer’s disease. The study shows PMN310's differentiation from other amyloid-beta-directed antibodies and its potential to improve efficacy and reduce risk associated with plaque-binding therapies. PMN310 is currently undergoing Phase 1a clinical studies, with promising initial data expected in mid-2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.